Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Gemox + Lenvatinib + Toripalimab in Advanced Intrahepatic Cholangiocarcinoma
NCT07304388Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2023
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, gemcitabine, lenvatinib, toripalimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen University. Started Feb 2023; status: completed.
02
Drugs
oxaliplatingemcitabinelenvatinibtoripalimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07304388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304388.